Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines

Virology. 2016 Feb:489:141-50. doi: 10.1016/j.virol.2015.09.015. Epub 2016 Jan 4.

Abstract

We investigated the effects on assembly and antigenic properties of specific modifications of the transmembrane spanning (TMS) and cytoplasmic tail (CT) domains of HIV-1 Env from a transmitted/founder (T/F) ZM53 Env glycoprotein. A construct containing a short version of the TMS domain derived from the mouse mammary tumor virus (MMTV) Env with or without a GCN4 trimerization sequence in the CT exhibited the highest levels of incorporation into VLPs and induced the highest titers of anti-Env IgG immune responses in a VLP context. Sera from guinea pigs immunized by VLPs with high Env content, and containing the CT trimerization sequence, had increased neutralization activity and antibody avidity. A cross-clade prime-boost regimen with clade B SF162 or clade C ZM53 Env DNA priming and boosting with VLPs containing modified ZM53 Env further enhanced these immune responses. The modified VLPs demonstrate improved potential as HIV-1 vaccine antigens.

Keywords: Antibody avidity; Cross-clade immunization; Cytoplasmic tail; Env glycoprotein; HIV-1; Immunogenicity; Neutralizing antibodies; Protein modification; Trimer stability; VLP vaccine.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • AIDS Vaccines / administration & dosage
  • AIDS Vaccines / chemistry
  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology
  • Amino Acid Motifs
  • Animals
  • Female
  • Guinea Pigs
  • HIV Antibodies / immunology
  • HIV Infections / immunology
  • HIV Infections / prevention & control*
  • HIV Infections / virology
  • HIV-1 / chemistry
  • HIV-1 / genetics
  • HIV-1 / immunology*
  • Humans
  • Immunization
  • Mice
  • Neutralization Tests
  • env Gene Products, Human Immunodeficiency Virus / administration & dosage
  • env Gene Products, Human Immunodeficiency Virus / chemistry*
  • env Gene Products, Human Immunodeficiency Virus / genetics
  • env Gene Products, Human Immunodeficiency Virus / immunology*

Substances

  • AIDS Vaccines
  • HIV Antibodies
  • env Gene Products, Human Immunodeficiency Virus